Saxenda Cost in Montana 2026: Cash Price, Insurance, Medicaid, and Compounded Liraglutide Options

What Is Saxenda and Why Does the Price Matter in Montana?

Saxenda is the brand name for liraglutide 3 mg, a once-daily subcutaneous injection approved by the FDA for chronic weight management in adults. Montana has roughly 1.1 million residents and a large rural geography, meaning many patients rely on mail-order pharmacies or telehealth services rather than brick-and-mortar clinics. Because the list price approaches $1,349 per month, access barriers can be steep for uninsured or Medicaid-enrolled Montanans.

How Liraglutide 3 mg Works

Liraglutide mimics the glucagon-like peptide-1 (GLP-1) hormone, slowing gastric emptying and increasing satiety signals in the hypothalamus. The FDA approved Saxenda in December 2014 for adults with a body mass index (BMI) of 30 or greater, or a BMI of 27 or greater in the presence of at least one weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia. The full prescribing information is available on the FDA accessdata portal.

Clinical Evidence Behind the Price Tag

The SCALE Obesity and Prediabetes trial, published in the New England Journal of Medicine in 2015, enrolled 3,731 participants and demonstrated that liraglutide 3 mg produced a mean weight loss of 8.4 kg (8.0%) versus 2.8 kg (2.6%) with placebo at 56 weeks [1]. That trial underpins every prescriber conversation about whether the drug's cost is justified. A 56-week course at Montana's 2026 cash price of approximately $1,349 per month totals roughly $18,900 before any discounts.

Separately, the SCALE Diabetes trial (N=846) showed a mean 6.0% body weight reduction with liraglutide 3 mg versus 2.0% placebo in adults with type 2 diabetes over 56 weeks, with P<0.001 for superiority [2]. These results helped establish the drug's place in obesity pharmacotherapy guidelines issued by the Endocrine Society, which state that "pharmacotherapy should be offered to patients with obesity when lifestyle changes alone are insufficient" [3].

Saxenda Cash Price in Montana in 2026

Retail Pharmacy Pricing

The Novo Nordisk manufacturer list price for Saxenda is $1,349 per month in 2026. Across Montana retail chains, including Walmart, Albertsons, and independent pharmacies in Billings, Missoula, Great Falls, and Bozeman, the cash price consistently tracks near that list price because no large pharmacy benefit manager (PBM) rebate flows to uninsured patients. GoodRx and similar discount platforms rarely reduce Saxenda below $1,200 per month because the drug has no generic competitor.

Mail-Order Pricing

Specialty mail-order pharmacies may offer marginally lower prices for 90-day supplies. Patients ordering a three-month supply through accredited mail-order programs have reported prices between $3,800 and $4,000, which works out to roughly $1,267 to $1,333 per month. Still, that represents only a 1% to 6% reduction from list price.

Why There Is No Generic

Liraglutide is a peptide drug manufactured through recombinant DNA technology. The FDA has not approved an interchangeable biosimilar or generic version of Saxenda as of early 2026. That regulatory status keeps prices anchored near the brand list price regardless of which Montana pharmacy a patient uses.

Does Montana Medicaid Cover Saxenda?

Montana Medicaid does not cover Saxenda as of 2026 [4]. The Montana Department of Public Health and Human Services (DPHHS) administers the state Medicaid program and has not added liraglutide 3 mg to its preferred drug list for weight management. This exclusion affects a significant portion of Montana's lower-income population, given that roughly 20% of Montana residents were enrolled in Medicaid as of the most recent CMS data [5].

Why Medicaid Does Not Cover It

Most state Medicaid programs exclude anti-obesity medications from their formularies under a longstanding federal policy that treated obesity as a lifestyle issue rather than a disease. Although CMS proposed changes to that framework in 2023 and 2024, Montana has not yet adopted expanded obesity drug coverage. Patients enrolled in Montana Medicaid who need pharmacotherapy for weight management may have access to older, cheaper agents such as phentermine or topiramate, but not liraglutide 3 mg.

Medicaid Managed Care Plans

Montana transitioned to a managed Medicaid model called Montana Medicaid Managed Care (MMMC). The managed care organizations (MCOs) operating in Montana follow the same DPHHS formulary restrictions, so Saxenda remains excluded across all MCO plans as well.

Which Private Insurance Plans Cover Saxenda in Montana?

Coverage varies by employer plan and insurer. The three largest commercial insurers operating in Montana are Blue Cross Blue Shield of Montana, PacificSource Health Plans, and Mountain Health CO-OP. None of them list Saxenda on their standard formularies for individual and small-group markets, though large self-insured employer plans sometimes negotiate different benefit designs.

Checking Your Specific Plan

Patients should call the member services number on the back of their insurance card and ask specifically: "Is liraglutide 3 mg (Saxenda, NDC 0169-4400-12) covered under my pharmacy benefit, and what tier?" Getting the answer in writing (or noting the call reference number) is advisable before filling a prescription, because verbal coverage confirmations are not binding.

Prior Authorization Requirements

When commercial plans do cover Saxenda, they virtually always require prior authorization (PA). Typical PA criteria require documentation of a BMI of 30 or greater (or 27 with a comorbidity), a record of at least three to six months of supervised diet and exercise without adequate weight loss, and confirmation that the patient does not have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. The FDA label carries a black-box warning for thyroid C-cell tumor risk seen in rodent studies, which PA reviewers consistently flag [6].

Step Therapy

Some plans also require step therapy, meaning a patient must first try and fail an older anti-obesity medication (typically phentermine/topiramate or bupropion/naltrexone) before the plan will authorize Saxenda. Documenting those prior attempts clearly in the medical record speeds the PA process.

Novo Nordisk Saxenda Savings Programs in Montana

The Saxenda Savings Card

Novo Nordisk offers a savings card for commercially insured patients who are not enrolled in a federal or state government insurance program (including Medicaid, Medicare, Tricare, or VA). Eligible Montana patients may pay as little as $25 per month for Saxenda after applying the savings card at a participating pharmacy. The savings card is not available to Medicaid or Medicare beneficiaries because of federal anti-kickback regulations.

Patients can enroll at NovoCare's patient assistance page. The card typically covers up to $200 per 30-day prescription fill, with an annual cap that Novo Nordisk adjusts periodically. Patients whose out-of-pocket cost after insurance exceeds that cap per fill pay the remainder at retail rates.

NovoCare Patient Assistance Program

For uninsured or underinsured Montana patients who meet income eligibility criteria (generally at or below 400% of the federal poverty level), the NovoCare Patient Assistance Program may supply Saxenda at no cost. Applications require proof of income, a physician prescription, and proof of Montana residency. Processing takes two to six weeks on average.

State Pharmaceutical Assistance Programs

Montana does not operate a state pharmaceutical assistance program (SPAP) that covers Saxenda. Patients should check NeedyMeds.org for updated program listings, as manufacturer programs change annually.

Compounded Liraglutide 3 mg in Montana: What Is Legal?

Compounded liraglutide 3 mg is available through licensed 503A compounding pharmacies operating in Montana. A 503A pharmacy compounds medications for individual patients based on a valid prescription from a licensed practitioner. Under federal and Montana state law, 503A pharmacies may compound liraglutide provided the bulk drug substance used meets USP standards and a valid patient-specific prescription exists.

503A vs. 503B: The Legal Distinction

503A pharmacies serve individual patients and operate under state board of pharmacy oversight plus FDA oversight of the bulk drug substance. 503B outsourcing facilities produce larger batches for hospitals and clinics, and they are subject to stricter FDA current Good Manufacturing Practice (cGMP) requirements. Montana patients receiving compounded liraglutide from a 503A pharmacy are receiving a legally permissible product, assuming the pharmacy holds a current Montana Board of Pharmacy license.

The FDA's guidance on bulk drug substances for compounding is published at FDA.gov. Liraglutide is not on the FDA's 503B "bulk substance" list as of early 2026, which limits large-scale outsourcing facility production but does not prohibit 503A patient-specific compounding.

Is It the Same Drug?

Compounded liraglutide is not FDA-approved. It is not the same product as Saxenda in terms of regulatory status, quality assurance data, or clinical trial validation. The SCALE trials cited above used Novo Nordisk's proprietary liraglutide formulation. Prescribers and patients should discuss the differences in sterility testing, potency verification, and stability data between brand-name Saxenda and compounded liraglutide before choosing the compounded route [7].

Pricing for Compounded Liraglutide in Montana

Compounded liraglutide 3 mg from a 503A pharmacy in Montana can cost substantially less than brand-name Saxenda. Prices from licensed compounding pharmacies serving Montana patients have ranged from $150 to $350 per month depending on concentration, vial size, and dispensing fees. That represents a 74% to 89% reduction compared to the $1,349 brand list price. Insurance does not cover compounded medications in the same way it covers FDA-approved drugs, so patients pay out of pocket.

Can You Get a Saxenda Prescription via Telehealth in Montana?

Telehealth prescribing of Saxenda is permitted in Montana. Montana law allows licensed physicians, physician assistants, and nurse practitioners to prescribe Schedule IV controlled substances (Saxenda is not a controlled substance) and other prescription medications via synchronous audio-video telehealth visits, provided a valid prescriber-patient relationship is established. Montana also follows the Ryan Haight Act exemptions that apply to non-controlled substances, so liraglutide 3 mg prescriptions can be issued without an in-person visit [8].

What a Telehealth Visit Typically Includes

A qualifying telehealth visit for Saxenda prescription in Montana generally includes:

• Review of BMI, weight history, and current medications
• Screening for contraindications (personal or family history of MTC or MEN2, pancreatitis history, pregnancy)
• Discussion of diet and activity goals
• A written prescription sent electronically to a Montana-licensed pharmacy or a licensed mail-order pharmacy

Visits through HealthRX and similar telehealth platforms take approximately 20 to 30 minutes. After the initial visit, monthly follow-up appointments monitor weight loss progress, side effects (nausea, vomiting, and constipation affect 20% to 40% of patients in the first four to eight weeks), and dose titration from the starting 0.6 mg/day up to the 3.0 mg/day maintenance dose [6].

Dose Titration Schedule

The FDA-approved titration schedule escalates liraglutide in 0.6 mg weekly increments over five weeks:

• Week 1: 0.6 mg/day
• Week 2: 1.2 mg/day
• Week 3: 1.8 mg/day
• Week 4: 2.4 mg/day
• Week 5 onward: 3.0 mg/day

Slower titration (extending each step to two weeks) is sometimes used to reduce gastrointestinal side effects, though this extends the time to therapeutic dose.

Comparing Saxenda to Other GLP-1 Options Available in Montana

Montana patients prescribed a GLP-1 receptor agonist for weight management have a small but growing menu of options. Semaglutide 2.4 mg (Wegovy) was approved by the FDA in June 2021 for chronic weight management. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg once weekly produced 14.9% mean body weight loss at 68 weeks compared to 2.4% with placebo, a difference of 12.4 percentage points (P<0.001) [9]. That efficacy advantage over liraglutide's 8.0% in SCALE is a frequent reason prescribers prefer semaglutide when insurance coverage is available.

The list price for Wegovy is approximately $1,349 per month as well in 2026, nearly identical to Saxenda, but Wegovy is dosed once weekly rather than daily. For patients who struggle with daily injections, that dosing difference can affect adherence.

Tirzepatide (Zepbound), approved for weight management in November 2023, showed 20.9% mean weight loss at 72 weeks in the SURMOUNT-1 trial (N=2,539) at the 15 mg dose [10]. Its list price exceeds $1,000 per month, and Montana Medicaid does not cover it either.

Practical Decision Guide: Which Route Makes Sense for Montana Patients?

The right choice depends on insurance status, income, and clinical factors.

Commercially insured patients should confirm Saxenda coverage and apply for the Novo Nordisk savings card. If coverage is denied, an appeal citing Endocrine Society guidelines and the SCALE trial data strengthens the case [3].

Medicaid-enrolled patients have no Saxenda coverage under Montana Medicaid in 2026 and should ask their prescriber about the NovoCare Patient Assistance Program or consider licensed 503A compounded liraglutide if cost is the primary barrier.

Uninsured patients face the sharpest cost challenge. Compounded liraglutide from a licensed Montana 503A pharmacy offers the most affordable entry point at $150 to $350 per month, though the absence of FDA-approval-level quality data is a trade-off patients should discuss explicitly with their prescriber.

Rural Montana patients without a nearby endocrinologist or obesity medicine specialist can access telehealth prescribing legally, making geography less of a barrier than the cost itself.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states that "access to anti-obesity medications remains unacceptably limited due to cost barriers and insurance exclusions, and clinicians should proactively explore all available patient assistance resources" [3].